155 related articles for article (PubMed ID: 36403606)
21. An update on the topical and oral therapy options for treating pediatric atopic dermatitis.
Glines KR; Stiff KM; Freeze M; Cline A; Strowd LC; Feldman SR
Expert Opin Pharmacother; 2019 Apr; 20(5):621-629. PubMed ID: 30601075
[TBL] [Abstract][Full Text] [Related]
22. Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients With Atopic Dermatitis Treated With Dupilumab: A US Multidatabase Cohort Study.
Schneeweiss MC; Wyss R; Chin K; Merola JF; Silverberg JI; Mostaghimi A; Schneeweiss S
Dermatitis; 2022 Nov-Dec 01; 33(6S):S73-S82. PubMed ID: 35170520
[TBL] [Abstract][Full Text] [Related]
23. Safety of dupilumab in a 5-month-old infant with severe atopic dermatitis.
Havele SA; Khurana MC; McMahon P; Murthy AS; Perman MJ; Treat JR
Pediatr Dermatol; 2022 Mar; 39(2):291-294. PubMed ID: 35434859
[TBL] [Abstract][Full Text] [Related]
24. Dupilumab after the 2017 approval for the treatment of atopic dermatitis: what's new and what's next?
van der Schaft J; Thijs JL; de Bruin-Weller MS; Balak DMW
Curr Opin Allergy Clin Immunol; 2019 Aug; 19(4):341-349. PubMed ID: 31145194
[TBL] [Abstract][Full Text] [Related]
25. Systemic Agents for Severe Atopic Dermatitis in Children.
Notaro ER; Sidbury R
Paediatr Drugs; 2015 Dec; 17(6):449-57. PubMed ID: 26547214
[TBL] [Abstract][Full Text] [Related]
26. Long-term effectiveness and safety of treatment with dupilumab in patients with atopic dermatitis: Results of the TREAT NL (TREatment of ATopic eczema, the Netherlands) registry.
Bosma AL; de Wijs LEM; Hof MH; van Nieuwenhuizen BR; Gerbens LAA; Middelkamp-Hup MA; Hijnen D; Spuls PI
J Am Acad Dermatol; 2020 Nov; 83(5):1375-1384. PubMed ID: 32485210
[TBL] [Abstract][Full Text] [Related]
27. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
[TBL] [Abstract][Full Text] [Related]
28. Systemic therapy of atopic dermatitis in children and adults.
Simon D
Curr Probl Dermatol; 2011; 41():156-164. PubMed ID: 21576956
[TBL] [Abstract][Full Text] [Related]
29. Real-world persistence with dupilumab among adults with atopic dermatitis.
Silverberg JI; Guttman-Yassky E; Gadkari A; Kuznik A; Mallya UG; Mastey V; Zhang H; Chen Z; Chen C; Korotzer A; Sierka D; Fenton MC; Kaur M; Jalbert JJ
Ann Allergy Asthma Immunol; 2021 Jan; 126(1):40-45. PubMed ID: 32739313
[TBL] [Abstract][Full Text] [Related]
30. Dupilumab use in atopic dermatitis and beyond in skin diseases.
Fourzali K; Golpanian RS; Yosipovitch G
Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
[TBL] [Abstract][Full Text] [Related]
31. Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients.
Pino Lopez J; Kromer C; Herr R; Schmieder A; Bayerl C; Schaarschmidt ML
Eur J Dermatol; 2021 Apr; 31(2):233-238. PubMed ID: 33871362
[TBL] [Abstract][Full Text] [Related]
32. Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase IIa open-label trial and subsequent phase III open-label extension.
Cork MJ; Thaçi D; Eichenfield LF; Arkwright PD; Hultsch T; Davis JD; Zhang Y; Zhu X; Chen Z; Li M; Ardeleanu M; Teper A; Akinlade B; Gadkari A; Eckert L; Kamal MA; Ruddy M; Graham NMH; Pirozzi G; Stahl N; DiCioccio AT; Bansal A
Br J Dermatol; 2020 Jan; 182(1):85-96. PubMed ID: 31595499
[TBL] [Abstract][Full Text] [Related]
33. Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis: 1-Year Results From the RELIEVE-AD Study.
Strober B; Mallya UG; Yang M; Ganguli S; Gadkari A; Wang J; Sierka D; Delevry D; Kimball AB
JAMA Dermatol; 2022 Feb; 158(2):142-150. PubMed ID: 34910086
[TBL] [Abstract][Full Text] [Related]
34. Dupilumab Versus Cyclosporine for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults: Indirect Comparison Using the Eczema Area and Severity Index.
Ariëns LFM; Gadkari A; van Os-Medendorp H; Ayyagari R; Terasawa E; Kuznik A; Chen Z; Bégo-Le Bagousse G; Lu Y; Rizova E; Graham NMH; Pirozzi G; De Bruin-Weller M; Eckert L
Acta Derm Venereol; 2019 Sep; 99(10):851-857. PubMed ID: 31099402
[TBL] [Abstract][Full Text] [Related]
35. Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2.
Cork MJ; Eckert L; Simpson EL; Armstrong A; Barbarot S; Puig L; Girolomoni G; de Bruin-Weller M; Wollenberg A; Kataoka Y; Remitz A; Beissert S; Mastey V; Ardeleanu M; Chen Z; Gadkari A; Chao J
J Dermatolog Treat; 2020 Sep; 31(6):606-614. PubMed ID: 31179791
[No Abstract] [Full Text] [Related]
36. Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events.
Geba GP; Li D; Xu M; Mohammadi K; Attre R; Ardeleanu M; Musser B
J Allergy Clin Immunol; 2023 Mar; 151(3):756-766. PubMed ID: 36084766
[TBL] [Abstract][Full Text] [Related]
37. Treatment outcomes of patients with Atopic Dermatitis (AD) treated with dupilumab through the Early Access to Medicines Scheme (EAMS) in the UK.
O'Kane D; Davis L; Ardern-Jones M; Laws P; Shaw L; Cork M; Velangi S; Cooper HL; Hudson R; Smith AB; Rout R
Ulster Med J; 2021 May; 90(2):70-76. PubMed ID: 34276083
[TBL] [Abstract][Full Text] [Related]
38. Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis.
Beck LA; Deleuran M; Bissonnette R; de Bruin-Weller M; Galus R; Nakahara T; Seo SJ; Khokhar FA; Vakil J; Xiao J; Marco AR; Levit NA; O'Malley JT; Shabbir A
Am J Clin Dermatol; 2022 May; 23(3):393-408. PubMed ID: 35503163
[TBL] [Abstract][Full Text] [Related]
39. Long-term real-world experience of the side effects of dupilumab in 128 patients with atopic dermatitis and related conditions aged 6 years and above: Retrospective chart analysis from a single tertiary care center.
Parmar NV; Abdula MA; Al Falasi A; Krishna CV
Dermatol Ther; 2022 May; 35(5):e15415. PubMed ID: 35238115
[TBL] [Abstract][Full Text] [Related]
40. TREatment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema.
Bosma AL; Spuls PI; Garcia-Doval I; Naldi L; Prieto-Merino D; Tesch F; Apfelbacher CJ; Arents BWM; Barbarot S; Baselga E; Deleuran M; Eichenfield LF; Gerbens LAA; Irvine AD; Manca A; Mendes-Bastos P; Middelkamp-Hup MA; Roberts A; Seneschal J; Svensson Å; Thyssen JP; Torres T; Vermeulen FM; Vestergaard C; von Kobyletzki LB; Wall D; Weidinger S; Schmitt J; Flohr C
Br J Dermatol; 2020 Jun; 182(6):1423-1429. PubMed ID: 31444799
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
